Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and antitumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

被引：0
|
作者：
Olszanski, A. J. [1 ]
Luke, J. J. [2 ]
LoRusso, P. M. [3 ]
Falchook, G. S. [4 ]
Bedard, P. L. [5 ]
Sanborn, R. E. [6 ]
Patel, S. P. [7 ]
Orr, D. [8 ]
Gibbs, J. P. [9 ]
Li, C. [9 ]
Huang, Y-C. [9 ]
Gregory, R. [9 ]
Perera, S. [9 ]
Xu, R. [9 ]
Joshi, A. [9 ]
Lee, M. Y. [9 ]
Raizer, J. [9 ]
Gao, X. [10 ]
机构：
[1] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA
[2] Univ Pittsburgh, Canc Immunotherapeut Ctr, Med, Pittsburgh, PA USA
[3] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[4] Sarah Cannon Res Inst SCRI HealthONE, Drug Dev Unit, Denver, CO USA
[5] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada
[6] Earle A Chiles Res Inst, Providence Canc Inst, Oncol, Portland, OR USA
[7] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[8] Mary Crowley Canc Res, Oncol, Dallas, TX USA
[9] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[10] Massachusetts Gen Hosp, Med, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029P
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [11] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
    Amita Patnaik
    Glen J. Weiss
    Drew W. Rasco
    Lisa Blaydorn
    Amy Mirabella
    Murali Beeram
    Wei Guo
    Sharon Lu
    Hadi Danaee
    Kristen McEachern
    Ellie Im
    Jasgit C. Sachdev
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103
  • [12] Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
    Seto, Takashi
    Esaki, Taito
    Hirai, Fumihiko
    Arita, Shuji
    Nosaki, Kaname
    Makiyama, Akitaka
    Kometani, Takuro
    Fujimoto, Chinatsu
    Hamatake, Motoharu
    Takeoka, Hiroaki
    Agbo, Felix
    Shi, Xiaojin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [13] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Gazzah, Anas
    Bahleda, Rastislav
    Menis, Jessica
    Champiat, Stephane
    El-Dakdouki, Yolla
    Paoletti, Xavier
    Ribrag, Vincent
    Michot, Jean-Marie
    Rafie, Saloomeh
    Planchard, David
    Besse, Benjamin
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    CANCER RESEARCH, 2018, 78 (13)
  • [14] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Besse, Benjamin
    Planchard, David
    Champiat, Stephane
    Angevin, Eroc
    Hollebecque, Antoine
    Bahleda, Rastislav
    Gazzah, Anas
    Armand, Jean-Pierre
    Paoletti, Xavier
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [15] A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    VerMeulen, W.
    Harper, K.
    Liu, G.
    Tye, L.
    Chao, R.
    Traynor, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [16] A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
    Liu, Q.
    Liu, B.
    Wei, J.
    Li, R.
    Shao, J.
    Zhu, L.
    Tian, M.
    Yu, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1498 - S1498
  • [17] Phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Traynor, A. M.
    Sandler, A. B.
    Schiller, J. H.
    Ilagan, J.
    Vermeulen, W. L.
    Liu, G.
    Tye, L.
    Verkh, L.
    Chao, R.
    Robert, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [18] Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors
    Lickliter, J.
    Mileshkin, L.
    Voskoboynik, M.
    Millward, M.
    Freimund, A.
    Meniawy, T.
    Tang, T.
    Wei, R.
    Li, M.
    Paton, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [19] Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
    Sausville, E. A.
    LoRusso, P.
    Carducci, M. A.
    Barker, P. N.
    Agbo, F.
    Oakes, P.
    Senderowicz, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [20] Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey Alan
    Pavlick, Anna C.
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha A.
    Walker, Russell M.
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345